HK Stock Market Move | METIS TECHBIO-P(07666) rose nearly 5% and formed a strategic alliance with Deerfield to jointly develop AI-driven protein drugs and in vivo immune therapy.

METIS TECHBIO-P (07666) rose nearly 5% at the time of release, up 4.47% to 15.44 Hong Kong dollars, with a turnover of 8.2235 million Hong Kong dollars. On the news front, on May 28th, according to the official WeChat account of Metis Techbio, the company announced a strategic alliance with the global top health investment and innovation platform Deerfield Management. The two parties will jointly develop a new generation of in vivo protein therapeutics and immunotherapies, and jointly promote the global commercialization of collaborative pipeline products. Deerfield will conduct in-depth cooperation on Metis Techbio's self-developed AI nanodelivery platform NanoForge and its driving solutions and core pipeline projects in global clinical development and business expansion initiatives. This includes a leading T-cell engager (TCE) project discovered and advanced to the pre-clinical candidate (PCC) stage using Metis Techbio's self-developed AiProtein platform. Deerfield will further explore potential licensing and development opportunities for this project to support its entry into the IND supportive research and clinical development stage.